Abstract
Several forms of pulmonary disease occur among patients treated with amiodarone, i.e. chronic interstitial pneumonitis, organizing pneumonia, ARDS, a solitary pulmonary mass of fibrosis. The prevalence is estimated to be about 5%. Two major hypotheses of amiodarone-induced pulmonary injury include direct cytotoxicity and a hypersensitivity reaction. Given the frequency and potential severity of amiodarone-induced pulmonary toxicity, early detection is desirable. Unfortunately, there are no adequate predictors of pulmonary toxicity due to amiodarone. Patients who should benefit from amiodarone should be carefully selected and the lowest effective dosage of amiodarone should be taken. Amiodarone-induced pulmonary toxicity is a diagnosis of exclusion. Pulmonary evaluation with chest X-ray and pulmonary function testing, including diffusion capacity for carbon monoxide is recommended when amiodarone is started. A documented decline in the diffusing capacity of greater than 20% is useful in suggesting the need for closer monitoring or for further diagnostic testing. Although the optimal frequency of follow-up has not been determined, most cases of amiodarone-induced lung injury develop during the first 2 years of treatment and disease onset usually is slow. Pulmonary function tests and imaging may be performed every 3–6 months, depending on the presumed individual risk. Treatment of amiodarone pulmonary toxicity consists primarily of stopping amiodarone. Corticosteroid therapy can be life-saving for severe cases and for patients with less severe disease in whom withdrawal of amiodarone is not desirable. Due to its accumulation in fatty tissues and long elimination half-life, pulmonary toxicity may initially progress despite drug discontinuation and may recur after steroid withdrawal. The prognosis of amiodarone lung disease is generally favourable.
Similar content being viewed by others
References
Adams G, Kehoe R, Lesch M, Glassroth J (1988) Amiodarone-induced pneumonitis. Assessment of risk factors and possible risk reduction. Chest 93:254–263
Adverse Drug Reactions Advisory Committee (2005) The multiple toxicities of amiodarone. Aust Adv Drug React Bull 24:11
Al-Khatib S, LaPointe N, Curtis L et al (2003) Outpatient prescribing of antiarrythmic drugs from 1995 to 2000. Am J Cardiol 91:91–94
Amiodarone Trials Meta-Analysis Investigators (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 350:1417–1424
Ashrafian H, Davey P (2001) Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest 120:275–282
Azzam I, Tov N, Elias N, Naschitz J (2006) Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy. Postgrad Med J 82:73–75
Bargout R, Jankov A, Dincer E et al (2000) Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 278:L1039–L1044
Beasley M, Franks T, Galvon J et al (2002) Acute fibrinous and organizing pneumonia. A histologic pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 126:1064–1070
Bedrossian C, Warren C, Ohar J, Bhan R (1997) Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol 1:47–56
Brien J, Jimmo S, Brennan F et al (1987) Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol 65:360–364
Camus P, Martin W, Rosenow E (2004) Amiodarone pulmonary toxicity. Clin Chest Med 25:65–75
Connolly S (1999) Evidence based analysis of amiodarone efficacy and safety. Circulation 100:2025–2034
Coudert B, Bailly F, André F et al (1992) Amiodarone pneumonitis: bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 102:1005–1012
Donaldson L, Grant I, Naysmith M, Thomas J (1998) Acute amiodarone-induced lung toxicity. Intensive Care Med 24:626–630
Dusman R, Stanpon M, Miles W et al (1990) Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82:51–59
Endoh Y, Hanai R, Uto K et al (2000) KL_6 as a potential new marker for amiodarone-induced pulmonary toxicity. Am J Cardiol 86:229–231
Ernawati D, Stafford L, Hughes J (2008) Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 66:82–87
Ghezel-Ahmadi V, Kürschner V, Fisseler-Eckhoff A et al (2008) Amiodaroninduzierte pneumonitis. Anaesthesist 57:982–9877
Goldstein I, Topilsky M, Segev D et al (1997) Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. Chest 111:1446–1447
Haas N, Camphausen C (2008) Acute hemodynamic effects of intravenous amiodarone treatment in pediatric patients with cardiac surgery. Clin Res Cardiol 97:801–810
Haas N, Wegendt C, Schäffler R et al (2008) ECMO for cardiac rescue in a neonate with accidental amiodarone overdose. Clin Res Cardiol 97:878–881
Handschin Am Lardinois D, Schneiter D et al (2003) Acute amiodarone-induced pulmonary toxicity following lung resection. Respiration 70:310–312
Hohnloser S, Crijns H, van Eickels M et al (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678
Hughes M, Binning A (2000) Intravenous amiodarone in intensive care. Intensive Care Med 26:1730–1739
Jessurun G, Boersma W, Crijns H (1998) Amiodarone-induced pulmonary toxicity: predisposing factors, clinical symptoms and treatment. Drug Saf 18:339–344
Kaushik S, Hussain A, Clarke P, Lazar H (2001) Acute pulmonary toxicity after low-dose amiodarone therapy. Ann Thorac Surg 72:1760–1761
Kay G, Epstein A, Kirklin J et al (1988) Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 62:490–492
Kharabsheh S, Abendroth C, Kozak M (2002) Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 89:896–898
Kober L, Torp-Pedersen C, McMurray J et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358:2678–2687
Lehmann L, Weichert W, Schnapauff D, Dietz R, Stockburger M (2008) Interstitial pneumonitis with accumulation of intraalveolar macrophages, a facet Amiodarone therapy. Clin Res Cardiol 97:917–920
Magro S, Lawrence E, Wheeler S et al (1988) Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 12:781–788
Malhorta A, Muse V, Mark E (2003) An 82-year-old man with dyspnea and pulmonary abnormalities. N Engl J Med 348:1574–1585
Martin W, Rosenow E (1988) Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 1). Chest 93:1067–1075
Martin W, Rosenow E (1988) Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 93:1242–1248
Mason J (1987) Amiodarone. N Engl J Med 316:455
Massey T, Leeder R, Rafeiro E, Brien J (1995) Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Can J Physiol Pharmacol 73:1675–1685
Van Mieghem W, Coolen L, Malysse I et al (1994) Amiodarone and the development of ARDS after lung surgery. Chest 105:1642–1645
Naccarelli G, Wolbrette D, Patel H et al (2000) Amiodarone: clinical trials. Curr Opin Cardiol 15:64–72
Nägele H, Behrens S, Castel A (2008) Ventricular tachycardia and aggravation of Brugada ECG pattern in a patient with coronary artery disease and combined amiodarone and betablocker therapy. Clin Res Cardiol 97:56–60
Nagata N, Suematsu R, Yoshii C et al (1997) Characterization of amiodarone pneumonitis as related to inflammatory cells and surfactant apoprotein. Chest 112:1068–1074
Ohar J, Jackson F, Redd R et al (1989) Usefulness of serial pulmonary function testing as an indicator of amiodarone toxicity. Am J Cardiol 64:1322–1326
Olshansky B, Sami M, Rubin A et al (2005) Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 95:404–405
Ott M, Khoor A, Leventhal J et al (2003) Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 123:646–651
Oyama N, Yokoshiki H, Kamishima T et al (2005) Detection of amiodarone-induced pulmonary toxicity in supine and prone positions––high-resolution computed tomography study. Circ J 69:466–470
Polkey M, Wilson P, Rees P (1995) Amiodarone pneumonitis: no safe dose. Respir Med 89:233–235
Polverosi R, Zanellato E, Doroldi C (1996) Thoracic radiography and high-resolution computerized tomography in the diagnosis of pulmonary disorders caused by amiodarone. Radiol Med 92:58–62
Ren H, Kuhlman J, Hruban R et al (1990) CT-pathology correlation of amiodarone lung. J Comput Assist Tomogr 14:760–765
Roden D (1999) Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. Am J Cardiol 84:29R–36R
Rodriguez-Garcia J, Garcia-Nieto J, Ballesta F et al (2001) Pulmonary mass and multiple lung nodules mimicking a lung neoplasm as amiodarone-induced pulmonary toxicity. Eur J Intern Med 12:372–376
Rossi S, Erasmus J, McAdams P et al (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 5:1245–1259
Ruangchira-Urai R, Colby T, Klein J et al (2008) Nodular amiodarone lung disease. Am J Surg Pathol 32:1654–1660
Singh B, Connolly S, Crijns H et al (2007) Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357:987–999
Singh S, Fletcher R, Fisher S et al (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77–82
Singh S, Fisher S, Deedwania P et al (1997) Pulmonary effects of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators. J Am Coll Cardiol 30:514–517
Siniakowicz R, Narula D, Suster B, Steinberg J (2001) Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan. J Cardiovasc Electrophysiol 12:431–436
Stelfox H, Ahmed S, Fiskio J, Bates D (2004) Monitoring amiodarone’s toxicities: recommendations, evidence, and clinical practice. Clin Pharmacol Ther 75:110–122
Vassallo P, Rohmann R (2007) Prescribing amiodarone. JAMA 298:1312–1322
Vernhet H, Bousquet C, Durand G et al (2001) Reversible amiodarone-induced lung disease: HRCT findings. Eur Radiol 11:1697–1703
Vorperian V, Havighurst T, Miller S et al (1997) Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 30:791–798
Weinberg B, Miles W, Klein L et al (1993) Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 125:109–120
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schwaiblmair, M., Berghaus, T., Haeckel, T. et al. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?. Clin Res Cardiol 99, 693–700 (2010). https://doi.org/10.1007/s00392-010-0181-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-010-0181-3